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doi:10.1016/j.jmii.2011.11.005Background: An increased incidence of vancomycin-resistant enterococcal bloodstream infec-
tions (VRE BSI) in the United States has been noted in recent years. There were a few reports of
VRE BSI in Taiwan. This study is intended to show the epidemiology, clinical features and
outcomes of VRE BSI at a medical center in southern Taiwan.
Methods: A retrospective study was conducted from January 1, 2005 to December 31, 2010. All
patients with VRE BSI episodes were identified and their medical records were reviewed.
Results: A total of 69 episodes of VRE BSI were identified in the study period. The incidence
rate increased from 0.01 episodes of VRE BSI/1000 patient-days in 2005 to 0.07 episodes of
VRE BSI/1000 patient-days in 2010. The 30-day mortality rate was 52.17% for all patients with
VRE BSI. The mortality rate of patients who received in vitro active and inactive antimicrobial
therapy for VRE BSI was 40% and 100%, respectively (p < 0.001). Factors associated with
mortality were shock [odds ratio (OR) 24.4, 95% confidence interval (CI) 3.6e163.2,
pZ 0.001], renal failure (OR 90.9, 95% CI 1.9e4404.3, pZ 0.02), and underlying liver cirrhosis
(OR 12.4, 95% CI 1.2e125.8, p Z 0.03). Use of linezolid for VRE BSI showed a trend for lower
30-day mortality than daptomycin therapy (35.5% vs. 56.3%, p Z 0.17).
Conclusion: VRE BSI is increasingly important in the study hospital and is associated with
a significant mortality rate. Appropriateness of antimicrobial therapy has a prognostic impact
on patients with VRE BSI.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.of Internal Medicine, National Cheng Kung University Hospital, Number 138, Sheng Li Road, Tainan
u.edu.tw (W.-C. Ko).
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222 C.-H. Chou et al.Introduction with VRE bacteremia between January 2005 and DecemberVancomycin-resistant enterococci (VRE) emerged in the
late 1980s and over the past 20 years the prevalence of VRE
has increased rapidly in many countries. In the United
States, 14e25% of all clinical enterococci isolates1e3 and
60% of Enterococcus faecium isolates from nosocomial
bloodstream infections (BSIs) were resistant to vancomy-
cin.4 The prevalence of VRE isolates from clinical specimens
in our institution was low between 1995 and 2005,
accounting for 0.55% of enterococcal isolates, with 61% of
VRE isolates identified as Enterococcus faecalis with a VanA
phenotype, and 39% E faecium with a VanB phenotype.5
BSIs due to VRE have been associated with a poor prog-
nosis. Two meta-analyses have shown that vancomycin
resistance was an independent factor for death among
patients with enterococcal BSIs.6,7
Despite the high mortality of VRE BSIs, the optimal
treatment is unclear. Teicoplanin, a glycopeptide available
in Europe, Taiwan and other countries, but not in the
United States, is generally in vitro active against VRE with
the VanB phenotype.8 There were very limited reports
about the use of teicoplanin for human VRE infections.9 A
clinical concern is the emergence of resistant mutants
during teicoplanin therapy.10 Quinupristin/dalfopristin and
linezolid have been approved by the US Food and Drug
Administration (FDA) for VRE infections. Clinical use of
quinupristin/dalfopristin was limited by the requirement of
a central line for infusion, side effects, and a lack of
activity against E faecalis. Linezolid has a better tolera-
bility, oral bioavailability and coverage against E faecalis;
however, its use is associated with bone marrow toxicity
and neuropathy. Additionally, VRE isolates that are resis-
tant to linezolid have been identified with subsequent
reports of nosocomial transmission in hospitals.11e13
Daptomycin has in vitro activity against VRE, including
strains that exhibit resistance to quinupristin/dalfopristin
and linezolid.14,15 The FDA approved daptomycin for the
treatment of complicated skin and soft tissue infections
and Staphylococcus aureus bacteremia, including right-
sided infective endocarditis, but not for VRE infections.16
Clinical data and treatment outcomes supporting the use
of daptomycin in the treatment of VRE infections are
limited to a few case reports and case series.17,18 Thus, the
objective of this study is to investigate the epidemiology,
clinical features and outcome of VRE BSIs in a tertiary
hospital in southern Taiwan, with emphasis on different
antimicrobial therapies for VRE BSI and factors associated
with mortality.Material and methods
Study design and source of patients
A retrospective study was conducted at National Cheng
Kung University Hospital, a 1000-bed academic tertiary care
hospital located in southern Taiwan. Infection control
measures, including a real-time laboratory-based reporting
system, contact isolation, and VRE surveillance protocols
have been launched at this hospital. The list of patients2010 was identified in the database of the Clinical Micro-
biology Laboratory and Center of Infection Control.
Systematic review of medical records
Medical charts of patients with at least a positive blood
culture for VRE during the study period were reviewed. A
standardized form was used to systematically collect
information regarding demographic, underlying disease and
clinical characteristics of each case. Adult patients aged
>18 years with clinically significant VRE BSI occurring
between January 2005 and December 2010 were included in
the analysis. Clinically significant VRE BSI was defined as
the isolation of VRE from two or more separately obtained
blood cultures, or isolation of VRE from a single blood
culture with clinical features compatible with sepsis.3
Recurrent VRE BSI was defined as another VRE bacteremic
episode at least 30 days apart from completion of antimi-
crobial therapy for the first VRE BSI episode. Recent inva-
sive procedure was defined as any invasive procedure or
surgical intervention within 30 days prior to the VRE
bacteremia. Recent hospitalization was defined as admis-
sion to the hospital within the previous 30 days. Thirty-day
mortality was defined as death due to any cause within
30 days after the onset of VRE BSI. The severity of co-
morbidity was measured by the Charlson Comorbidity
Index (CCI).19 Prescription of daptomycin and linezolid
required the approval from an infectious disease specialist
in the study hospital. Appropriate antimicrobial therapy
was defined as the receipt of at least one in vitro active
antimicrobial agent such as linezolid, daptomycin, or tei-
coplanin against VRE for at least 48 hours. Other regimens
were considered as inappropriate therapy. Clinical events
associated with organ system failure were assessed by the
criteria specified in the organ dysfunction and/or infection
score.20
VRE identification and antimicrobial susceptibility
test
For the laboratory identification of VRE, enterococci were
identified by the 6.5% NaCl and bile-esculin test, confirmed
by the Vitek Gram-positive identification system (bio-
Me´rieux, Marcy l’Etoile, France). Antimicrobial disk
susceptibility tests of vancomycin, ampicillin, high-level
streptomycin, high-level gentamicin, teicoplanin, and
linezolid (Becton Dickinson, Franklin Lakes, NJ, USA) were
performed. According to a previous surveillance program,
100% of vancomycin-resistant E faecalis, and 99.7% of
vancomycin-resistant E faecium were susceptible to dap-
tomycin.21 Susceptibility to daptomycin was not routinely
determined for VRE isolates in the study site. If there are
concerns regarding the susceptibility of VRE to daptomycin,
then the minimal inhibitory concentration (MIC) should be
determined using the E-test. The interpretive criteria of
the Clinical and Laboratory Standards Institute were used
to determine the susceptibilities of the isolates.22 The
interpretive criteria of the European Committee on Anti-
microbial Susceptibility Testing were used for teicoplanin
susceptibility. 23
Figure 1. Annual incidence of enterococcal bloodstream infection (BSI) and vancomycin-resistant enterococcal (VRE) BSI/1000
patient-days at National Cheng Kung University Hospital, 2005-2010.
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SPSS Statistics version 17.0 (SPSS Inc., Chicago, IL, USA),
was used for computing statistical tests. The trend in theTable 1 Comparison of survivors and fatal cases of vancomycin
Variablesa Total
(n Z 69)
Survivor
(n Z 33
Age, mean (SD), y 69.96 (11.67) 69.2 
Male gender 40 (57.97) 20 (60.6
Nursing home residency 8 (11.60) 5 (15.2)
Recent hospitalization 45 (65.22) 21 (63.6
Prior VRE colonization 14 (20.29) 6 (18.2)
Polymicrobial bacteremia 26 (37.68) 12 (36.4
Recent invasive procedure 41 (59.42) 18 (54.6
Charlson Co-morbidity Index 4.19 (2.40) 4.3  2
Pittsburgh Bacteremia Score 4.07 (2.91) 2.2  2
Comorbidities
Diabetes mellitus 32 (46.38) 17 (51.5
Hypertension 34 (49.28) 16 (48.5
Malignancy 22 (31.88) 13 (39.4
Chronic kidney diseases 16 (23.19) 9 (27.3)
Chronic obstructive pulmonary disease 7 (10.14) 4 (12.1)
Liver cirrhosis 11 (15.94) 3 (9.1)
Immunosuppression 3 (4.35) 1 (3.0)
Clinical features
Mechanical ventilation 38 (55.07) 9 (27.3)
Concomitant shock 40 (57.97) 8 (24.2)
Liver failure 23 (33.33) 4 (12.1)
Renal failure 17 (26.64) 1 (3.0)
Appropriate VRE treatment 54 (78.26) 33 (100
Time to appropriate antibioticc 3.60 (1.45) 3.7  1
a Data were expressed as cases (%) or means  standard deviations
b Variables in the univariate analysis with P values <0.5 and age we
c Time between bacteremia onset to the first dose of appropriate an
were included in the analysis.
CI Z confidence interval; OR Z odds ratio.incidence of VRE BSI over the study period was analyzed
with linear regression analysis. Continuous variables were
expressed as means  standard deviations (SD) and evalu-
ated by the Student t test. The categorical variables were-resistant Enterococcus (VRE) bacteremia
s
)
Fatal cases
(n Z 36)
Univariate Multivariate analysisb
p OR (95% CI) p
11.7 70.7  11.8 0.601 1.10 (1.00e1.20) 0.048
) 20 (55.6) 0.671
3 (8.3) 0.466
) 24 (66.7) 0.792
8 (22.2) 0.677
) 14 (38.9) 0.829
) 23 (63.9) 0.43 0.98 (0.25e3.83) 0.978
.9 4.0  1.9 0.611
.3 5.8  2.2 <0.001 1.83 (1.41e2.38) <0.001
) 15 (41.7) 0.413 1.79 (0.49e6.55) 0.384
) 18 (50.0) 0.9
) 9 (25.0) 0.2 1.55 (0.37e6.38) 0.548
7 (19.4) 0.441 1.58 (0.32e7.68) 0.573
3 (8.3) 0.702
8 (22.2) 0.137 12.40 (1.23e125.79) 0.033
2 (5.6) 1
29 (80.6) <0.001 0.97 (0.08e12.22) 0.981
32 (88.9) <0.001 24.37 (3.63e163.19) 0.001
19 (52.8) <0.001 2.13 (0.23-16.23) 0.468
16 (44.5) <0.001 90.92 (1.89-4404.29) 0.023
) 21 (58.3) <0.001 0.03 (0.01-0.12) <0.001
.4 3.5  1.6 0.553
.
re included in the multivariate analysis.
tibiotic against VRE. Only patients who received antibiotic for VRE
224 C.-H. Chou et al.evaluated by the Fisher exact test or X2 test, when
appropriate. Multiple regressions were used to determine
the effect of comorbidities, clinical features and antimi-
crobial therapy on mortality while controlling for cova-
riates. The covariates in the analysis included age, male
gender, CCI, presence of shock, acute renal and liver
failure, mechanical ventilation, and antimicrobial therapy.
Adjusted odds ratios and 95% confidence intervals were
calculated. A Cox proportional hazards model was used for
the survival curve, adjusted for confounding variables. All
tests were 2-tailed and a p value <0.05 was considered
statistically significant.Figure 2. The survival curve for patients with vancomycin-
resistant Enterococcus bacteremia with appropriate and inap-
propriate antimicrobial therapy, adjusted for age, gender,
Charlson comorbidity index, use of mechanical ventilation,
concomitant shock, renal and liver failure (Cox model)
(p < 0.001).Results
Over the 6 years, the rate of VRE BSI in our institution
increased significantly. Only 2.29% of Enterococcus isolates
causing BSI were resistant to vancomycin in 2005, but
increased to 19.05% in 2010. The incidence of VRE BSI
increased from 0.01 in 2005 to 0.07 VRE BSI/1000 patient-
days in 2010 (p Z 0.01, in trend) as shown in Fig. 1. The
incidence of VRE BSI increased significantly since 2008, and
the mortality rates from 2008 to 2010 were 71%, 59% and
79%, respectively.
Seventy episodes of VRE BSI were identified. Since
a patient had recurrent VRE BSI during the study period,
and only the first episode of this patient was included in the
analysis, there were 69 episodes included. Seven VRE
isolates were not available for species identification, so 52
isolates were identified as E faecium and 10 were Entero-
coccus gallinarum. No VRE bacteremic isolates were iden-
tified as E faecalis. The 30-day mortality rate for E faecium
and E gallinarum were similar, 52% and 50%, respectively.
The mean age of patients with VRE-BSI was 70.0 years, and
40% were males. Recent hospitalization and invasive
procedures were not infrequent. Diabetes mellitus, hyper-
tension and malignancies were common co-morbid
diseases. The mean CCI score was 4.2. The presence of
shock or respiratory failure after the onset of bacteremia
was noted in more than half of the patients.
Twelve (17.3%) patients received no antibiotic that was
active against VRE in vitro, and their 30-day mortality rate
was 100%. Of 12 fatal cases, 11 died before blood culture
results were available. Antibiotics with in vitro activity
against VRE were prescribed in 57 patients. Ten (14.5%)
patients were treated by teicoplanin, 31 (44.9%) linezolid,
and 16 (23.2%) daptomycin. None of the VRE isolates were
susceptible to ampicillin. The time between bacteremia
onset to the first dose of in vitro active antibiotic was 3.6
days. The mean CCI score in this study population was 4.2.
The 30-day mortality rate of those treated by an in vitro
effective drug was 42.1% and the overall mortality rate for
VRE BSI was 52.17%.
Patient characteristics for survivors and non-survivors
are compared in Table 1. Of note, 24 patients had poly-
microbial bacteremia, which was not associated with a fatal
outcome (14/26, 53.8% vs. 22/43, 51.25, p Z 0.83). In the
univariate analysis, several factors were associated with
mortality, including presence of shock (24.2% vs. 83.3%,
p < 0.001), acute renal failure (3.0% vs. 33.3%, pZ 0.002),
liver failure (12.1% vs. 45.8%, p Z 0.004), and respiratoryfailure (27.3% vs. 75.0%, p < 0.001). The above factors, in
addition to age, gender, presence of liver cirrhosis, malig-
nancy, CCI and appropriateness of antimicrobial therapy for
VRE BSI, were analyzed in a multivariable logistic regression
model. The presence of liver cirrhosis (OR 12.4, 95% CI
1.2e125.8, p < 0.03), shock (OR 24.4, 95% CI 3.6e163.2,
p Z 0.001) and acute renal failure (OR 90.9, 95% CI
1.9e4404.3, p Z 0.02) at the time of VRE BSI were inde-
pendently associated with mortality at 30 days (Table 1).
The Cox proportional hazards model was applied after
controlling for confounding variables. The result revealed
that the survival rate was significantly different between
patients with appropriate and inappropriate antimicrobial
therapy for VRE BSI (p < 0.001) (Fig. 2).
Clinical features of patients receiving either linezolid or
daptomycin therapy were compared in Table 2. Platelet
counts were lower in patients with daptomycin therapy
(pZ 0.001). Also hepatic failure (50.0% vs. 16.1%, pZ 0.02)
and the use of mechanical ventilation (68.8% vs. 35.5%,
p Z 0.03) at the time of VRE BSI were more common in
patients treated with daptomycin. However, there were no
differences in patients treated with linezolid or daptomycin
in terms of hospitalization days (74.9 vs. 49.9 days,
p Z 0.12) and 30-day mortality rate (35.5% vs. 56.3%,
p Z 0.17). As for teicoplanin therapy, it was used in 10
patients with bacteremia caused by VRE with a VanB
phenotype, with a mortality rate of 40%.
Discussion
The first study focusing on VRE bacteremia in Taiwan was
published in 2008 and only included 12 patients, with the
emphasis on clinical features and outcome but no mention
Table 2 Clinical characteristics of 47 patients with vancomycin-resistant Enterococcus (VRE) bacteremia treated by linezolid
or daptomycin
Variablesa Linezolid (n Z 31) Daptomycin (n Z 16) p
Age, y 72.2  11.1 68.3  11.8 0.281
Male gender 17 (54.8) 12 (75.0) 0.178
Nursing home residency 7 (22.6) 0 0.078
Recent hospitalization 22 (71.0) 11 (68.8) 1.000
Prior VRE colonization 9 (29.0) 2 (12.5) 0.287
Recent invasive procedure 18 (58.0) 8 (50.0) 0.598
Charlson co-morbidity index 4.3  2.3 4.6  3.2 0.632
Pittsburgh bacteremia score 3.4  2.9 3.9  2.5 0.579
Co-morbidities
Hypertension 18 (58.1) 9 (56.3) 0.905
Diabetes mellitus 17 (54.8) 8 (50.0) 0.753
Chronic kidney disease 9 (29.0) 5 (31.3) 1.000
Malignancy 7 (22.6) 7 (43.8) 0.182
Chronic obstructive pulmonary disease 5 (16.1) 2 (12.5) 1.000
Liver cirrhosis 3 (9.7) 3 (18.8) 0.395
Immunosuppression 0 1 (6.3) 0.304
Clinical features
Concomitant shock 14 (45.2) 9 (56.3) 0.471
Mechanical ventilation 11 (35.5) 11 (68.8) 0.030
Liver failure 5 (16.1) 8 (50.0) 0.020
Renal failure 4 (12.9) 3 (18.8) 0.676
Laboratory data
WBC, /mm3 12.8  6.5 11.7  8.5 0.637
Platelet count, 1000/mm3 185.0  127.7 90.2  64.4 0.001
Serum C-reactive protein, mg/L 91.4  89.7 112.2  80.8 0.451
Serum creatinine, mg/dL 2.2  2.4 2.2  3.0 0.984
Time to appropriate antibiotic,b d 3.7  1.3 3.5  1.6 0.709
Hospital stay, d 74.9  60.0 49.9  27.7 0.122
30-d mortality 11 (35.5) 9 (56.3) 0.172
a Data were expressed as cases (%) or means  standard deviations.
b Time between bacteremia onset to the first dose of effective antibiotic against VRE. Only patients who received antibiotic for VRE
were included in the analysis.
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study, with more clinical cases in Taiwan investigating
clinical characteristics, treatment and outcome of patients
with VRE bacteremia. Our findings provide important
insights into the epidemiology and management of difficult-
to-treat VRE infections. We observed an increasing rate of
vancomycin resistance in bacteremic Enterococcus isolates
during the 6-year study period, increasing from 2.3% in 2005
to 19.1% in 2010, with the incidence increasing from 0.01 to
0.07 VRE BSI/1000 patient-days. This trend in increasing
incidence rate of VRE infections was similar in a previous
study conducted from 2005 to 2008 in the USA,25 with an
almost three-fold increase in incidence from 0.06 to 0.17
infections/1000 patient-days. This local epidemiology
information reflects that VRE BSI is an emerging health-care
associated infection in Taiwan, as in the United States.
In this study, the 30-day mortality of patients with VRE
BSI was 52.17%. This high mortality rate is comparable to
published studies of VRE bacteremia.24e30 Among all
patients with VRE BSI, approximately 60% of patients have
concomitant shock and 55% of patients need mechanicalventilation at the time of VRE BSI. Moreover, a long hospital
stay, up to 62 days, was found. This suggests that patients
with VRE bacteremia had poor clinical conditions at the
time of VRE BSI, as reflected by high Pittsburg bacteremia
scores. All these factors may contribute to a high mortality
rate. Several host factors such as severe underlying
disease, shock, renal and liver failure at the time of VRE
BSI, and mechanical ventilation, have been recognized to
be independent predictors of mortality in patients with
VRE bacteremia.29,31,32 Our study confirmed previous
findings as we found a significant association between
shock (p Z 0.001), renal failure (p Z 0.02) and mortality.
Moreover, in the current study, an amendable factor to
improve clinical outcome is noted, and that is adminis-
tration of adequate in vitro active antimicrobial therapy
for VRE BSI.
To date, the optimal treatment for VRE BSI is still unclear.
To conduct a prospective, double-blinded, randomized,
placebo-controlled trial to compare the efficacy of dapto-
mycin and linezolid for VRE BSI will be difficult due to the
rarity of VRE BSI in the real world. Currently, clinical choices
226 C.-H. Chou et al.of teicoplanin, daptomycin or linezolid will be influenced
by the resistance profiles of VRE isolates, preference of
attending clinicians, or more importantly the patients’
underlying conditions, such as platelet count, renal function,
serum creatine kinase, or a history or current evidence of
myositis. There were few retrospective studies comparing
the treatment outcome of daptomycin and linezolid for VRE
BSI. Mave et al25 reported 98 patients with VRE bacteremia.
Sixty-eight patients were treated by linezolid and 30 by
daptomycin, with a corresponding mortality rate of 20.6%
and 26.7%, respectively. However, daptomycin therapy has
been associated with a higher relapse rate (2.9% vs. 6.7%).
Similar results were found in a multicenter cohort study
involving 101 patients with VRE BSI, in-hospital mortality was
46.3% for those treated by daptomycin and 29.4% by linezolid
(p Z 0.10).26 The latest study by McKinnell et al indicated
there was a higher microbiological failure rate (29.0% vs.
17.5%) or mortality rate (37.2% vs. 28.0%) for VRE BSIs
treated by daptomycin than those by linezolid.27 All studies
were done in the United States, and a trend towards a higher
mortality rate among individuals with daptomycin therapy
was found. However the difference did not reach statistical
significance. Concordantly, we found a similar trend.
However, such a result should not be considered to be
conclusive, as the poor prognosis was possibly influenced by
more cases of respiratory failure requiring mechanical
ventilation and liver failure in the daptomycin group. These
observations suggest that patients with poorer clinical
conditions were more likely to receive daptomycin and have
a grave prognosis.
The current study has several limitations. First, this is
a retrospective study with a small number of cases
analyzed, and the study population was heterogeneous.
Second, our study did not evaluate the type and appropri-
ateness of medical therapy for concurrent pneumonia. As
daptomycin will be inhibited by surfactants, there may be
a greater likelihood of a grave outcome in pulmonary
infections treated by daptomycin, which not found by our
retrospective study. Third, a significant number of patients
with concurrent bloodstream infections were observed.
Although the majority of patients also received appropriate
therapy for concurrent pathogens others than VRE, those
co-existing pathogens were heterogeneous, which may
variably influence the outcome.
In conclusion, VRE BSIs may become a challenge in the
near future due to increasing incidence and a high mortality
rate. Appropriateness of antimicrobial therapy may
improve survival, and more prospective studies are needed
to define the optimal treatment for VRE BSI.References
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